利妥昔单抗注射液联合化疗治疗B细胞非霍奇金淋巴瘤的疗效观察

Efficacy Observation of Rituximab Injection Combined with Chemotherapy in the Treatment of B-cell Non-Hodgkin Lymphoma

目的:观察利妥昔单抗注射液联合化疗治疗B细胞非霍奇金淋巴瘤(B-NHL)的疗效。方法:将2013年1月至2014年12月我院收治的71例B-NHL患者分为对照组(n=35例)和观察组(n=36例)。对照组给予常规化疗方案进行治疗,观察组在此基础上加用利妥昔单抗进行治疗,3个周期后评价其疗效及安全性。结果:观察组总有效率为91.67%,明显高于对照组的68.57%,对比差异有统计学意义(x2=5.979,P<0.05);观察组不良反应总发生率为41.67%,略低于对照组的45.71%,但无统计学差异(x2=0.118,P>0.05)。结论:利妥昔单抗注射液联合化疗治疗B-NHL中期疗效显著,且无严重不良反应,值得临床推广。

Objective： To observe the efficacy of Rituximab injection combined with chemotherapy in the treatment of B-cell Non-Hodgkin Lymphoma（B-NHL）. Methods： 71 cases of patients with B-NHL treated in our hospital from January 2013 to December2014 were divided into control group（n=35） and observation group（n=36）, the control group was treated with conventional chemotherapy,while the observation group was treated with Rituximab injection combined with chemotherapy, evaluated the clinical efficacy and safety of two groups after 3 cycles treatment. Results： Total effective rate of observation group was 91.67%, which was significantly higher than68.57% in control group, the difference was statistically significance（Х^2=5.979, P〈0.05）; Total incidence of adverse reactions in observation group was 41.67%, which was slightly lower than 45.71% in control group, but the difference was not statistically significant（Х^2=0.118, P〈0.05）. Conclusion： Rituximab injection combined with chemotherapy has remarkable mid-term efficacy in the treatment of B-NHL, and without serious adverse reaction, which is worthy of application.